D C Henry - JoVE Visualize

Showing results (1-10 of 8) with videos related to

Pageof 1

Sort By:

Antimicrobial Agents and Chemotherapy|May 21, 1998

Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study GroupK J Tack, D C Henry, W M Gooch, et al.

Toxicology and Applied Pharmacology|September 15, 1988

Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmosetC T Eason, A J Spencer, A Pattison, et al.

Clinical Therapeutics|August 27, 1999

Comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of acute bacterial sinusitisD C Henry, A Sydnor, G A Settipane, et al.

Toxicologic Pathology|January 1, 1989

Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrateA J Spencer, T A Barbolt, D C Henry, et al.

Clinical Therapeutics|April 22, 1999

Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study GroupD C Henry, D J Moller, J Adelglass, et al.

Clinical Therapeutics|June 11, 1999

Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infectionsB A Lipsky, B Miller, R Schwartz, et al.

Clinical Therapeutics|August 10, 1999

Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study GroupD C Henry, R C Nenad, A Iravani, et al.

Lancet (London, England)|December 8, 2009

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.

Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:

Pageof 1

Antimicrobial Agents and Chemotherapy|May 21, 1998

Five-day cefdinir treatment for streptococcal pharyngitis. Cefdinir Pharyngitis Study GroupK J Tack, D C Henry, W M Gooch, et al.

Toxicology and Applied Pharmacology|September 15, 1988

Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse, and marmosetC T Eason, A J Spencer, A Pattison, et al.

Clinical Therapeutics|August 27, 1999

Comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of acute bacterial sinusitisD C Henry, A Sydnor, G A Settipane, et al.

Toxicologic Pathology|January 1, 1989

Gastric morphological changes including carcinoid tumors in animals treated with a potent hypolipidemic agent, ciprofibrateA J Spencer, T A Barbolt, D C Henry, et al.

Clinical Therapeutics|April 22, 1999

Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study GroupD C Henry, D J Moller, J Adelglass, et al.

Clinical Therapeutics|June 11, 1999

Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infectionsB A Lipsky, B Miller, R Schwartz, et al.

Clinical Therapeutics|August 10, 1999

Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study GroupD C Henry, R C Nenad, A Iravani, et al.

Lancet (London, England)|December 8, 2009

Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.

Pageof 1